{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-051280","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.836897+00:00","generated_at":"2026-05-29T03:04:26.086620+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Foghorn discontinues FHD-286 in AML; prioritizes pipeline and Lilly collaboration","bullets":["FHD-286 + decitabine showed objective responses in Phase 1 but efficacy threshold not met for continued standalone development.","Company evaluating partnerships/ISTs for FHD-286; independent development halted.","Priorities: proprietary CBP, EP300, ARID1B programs and Lilly collaboration including SMARCA2 inhibitor FHD-909.","Cash of $267.4M as of Sept 30, 2024; runway into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-051280","json":"https://secwatch.observer/filing/0001628280-24-051280.json","markdown":"https://secwatch.observer/filing/0001628280-24-051280.md","text":"https://secwatch.observer/filing/0001628280-24-051280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024051280/0001628280-24-051280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024051280/fhtx-20241216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:04:26.086620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}